Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amyloidosis

C Friman1, T Pettersson

  • 1Department of Medicine, Helsinki University Central Hospital, Finland.

Current Opinion in Rheumatology
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Rheumatic diseases can cause amyloidosis, leading to musculoskeletal issues. This review covers amyloid A, light-chain, and beta 2-microglobulin amyloidosis, detailing their causes, symptoms, diagnosis, and treatments for rheumatologists.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiographers' perception on task shifting to nurses and assistant nurses within the radiography profession.

Radiography (London, England : 1995)·2020
Same author

Increased incidence of cancer in systemic lupus erythematosus: a Finnish cohort study with more than 25 years of follow-up.

Scandinavian journal of rheumatology·2018
Same author

Normal inflammasome activation and low production of IL-23 by monocyte-derived macrophages from subjects with a history of reactive arthritis.

Scandinavian journal of rheumatology·2013
Same author

Nanowear of salivary films vs. substratum wettability.

Journal of dental research·2012
Same author

Decline in the incidence of renal failure due to amyloidosis associated with inflammatory rheumatic diseases.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2011
Same author

Clinical experience in the treatment of pneumonia with cefuroxime.

Proceedings of the Royal Society of Medicine·2010

Area of Science:

  • Rheumatology
  • Immunology
  • Biochemistry

Background:

  • Amyloidosis is a significant complication of rheumatic diseases, often presenting with musculoskeletal symptoms.
  • Understanding the diverse forms of amyloidosis, including amyloid A, amyloid light-chain, and amyloid beta 2-microglobulin, is crucial for effective management.

Purpose of the Study:

  • To review current developments in amyloidosis associated with rheumatic diseases.
  • To discuss the pathogenesis, clinical manifestations, diagnosis, and therapy of key amyloidosis subtypes from a rheumatologist's perspective.

Main Methods:

  • Review of existing literature and clinical experience regarding amyloidosis in rheumatic diseases.
  • Discussion of the biology of serum amyloid A (SAA) and development of new assays.

Related Experiment Videos

  • Analysis of the role of modified beta 2-microglobulin in inflammation and bone resorption.
  • Evaluation of serum amyloid P component scintigraphy for diagnosis and monitoring.
  • Review of published guidelines for colchicine dosage in familial Mediterranean fever-associated amyloidosis.
  • Assessment of intensive chemotherapy and stem cell transplantation for amyloid light-chain amyloidosis.

    • Main Results:

    • The biology of serum amyloid A (SAA) has been elucidated, with new assays developed.
    • Modified beta 2-microglobulin may trigger inflammatory responses leading to bone resorption in amyloid beta 2-microglobulin amyloidosis.
    • Serum amyloid P component scintigraphy shows utility in diagnosis and monitoring.
    • Colchicine dosage guidelines for familial Mediterranean fever-associated amyloidosis are available.
    • Intensive chemotherapy and stem cell infusion show therapeutic promise for amyloid light-chain amyloidosis.

    Conclusions:

    • Amyloidosis presents a complex challenge in rheumatology, requiring a comprehensive understanding of its various forms.
    • Advances in diagnostics and therapeutics, including novel assays, scintigraphy, and intensive chemotherapy regimens, offer improved management strategies.
    • Further research into the pathogenic mechanisms and therapeutic interventions for amyloidosis in rheumatic diseases is warranted.